No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 5 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Anbio Biotechnology Class A Ordinary Shares (NNNN) stock was $4.90 as of Oct 6, 2026, 11:53 AM EDT, up 1.35% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -84.8%
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa.
Medical - Instruments & Supplies · Frankfurt am Main, HE
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
N/A
vs Estimate
N/A
Revenue
$4.74M
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1NNNN | $214.85M | $4.89 | +1.35% | -84.84% | N/A | N/A | N/A |
| 2CGEN | $214.96M | $2.27 | -1.58% | +41.48% | -18.39% | -9.42% | vs NNNN |
| 3PRLD | $215.21M | $3.78 | +0.27% | +155.31% | -33.98% | N/A | vs NNNN |
| 4NAGE | $215.44M | $2.71 | +0.93% | -61.15% | -15.72% | -1.06% | vs NNNN |
| 5LYEL | $214.17M | $8.74 | -3.64% | -48.74% | -48.18% | N/A | vs NNNN |
| 6RNAC | $210.08M | $7.15 | +0.14% | -29.81% | -44.03% | -33.65% | vs NNNN |
forward FY estimate
N/A
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$4.89
High
N/A
